Transformed Follicular Lymphoma clinical trials
8 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- CAR-T Followed by Bispecific Antibodies
- Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
- A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
- Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Transformed Follicular Lymphoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.